hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
Department of Medical Oncology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.|Department of Surgery, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Laura L
LL
Meijer
Department of Medical Oncology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.|Department of Surgery, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Jisce R
JR
Puik
Department of Medical Oncology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Godefridus J
GJ
Peters
Department of Surgery, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Geert
G
Kazemier
Department of Medical Oncology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.|Cancer Pharmacology Laboratory, Italian Association for Cancer Research Start-Up Unit, University of Pisa, Pisa, Italy.
Elisa
E
Giovannetti
D001650:Bile Duct Neoplasms; D001653:Bile Ducts, Intrahepatic; D017024:Chemotherapy, Adjuvant; D018281:Cholangiocarcinoma; D003841:Deoxycytidine / Q000031:analogs & derivatives; D006801:Humans; D016896:Treatment Outcome; D000093542:Gemcitabine
D003841:Deoxycytidine; D000093542:Gemcitabine